125 related articles for article (PubMed ID: 27100894)
21. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.
Tsimafeyeu I; Bratslavsky G
Oncology; 2015; 88(6):321-31. PubMed ID: 25678187
[TBL] [Abstract][Full Text] [Related]
22. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
23. Potential of transglutaminase 2 as a therapeutic target.
Caccamo D; Currò M; Ientile R
Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177
[TBL] [Abstract][Full Text] [Related]
24. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
25. Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.
Akbar A; McNeil NMR; Albert MR; Ta V; Adhikary G; Bourgeois K; Eckert RL; Keillor JW
J Med Chem; 2017 Sep; 60(18):7910-7927. PubMed ID: 28858494
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
27. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
28. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
29. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
30. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
[TBL] [Abstract][Full Text] [Related]
31. [Recurrent malignant epithelioid angiomyolipoma of kidney: report of a case].
DU J; Jin YL; He CY; Li M; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):275-6. PubMed ID: 20654131
[No Abstract] [Full Text] [Related]
32. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
33. [Non-metastatic clear cell renal carcinoma: prognostic significance of morphometric and biomolecular factors].
Iurin AG
Vopr Onkol; 2009; 55(2):177-82. PubMed ID: 19514371
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
[TBL] [Abstract][Full Text] [Related]
35. Déjà vu with a twist: transglutaminases in bioenergetics and transcriptional dysfunction in Huntington's disease.
Kazemi-Esfarjani P; La Spada AR
EMBO Mol Med; 2010 Sep; 2(9):335-7. PubMed ID: 20730854
[TBL] [Abstract][Full Text] [Related]
36. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
37. Calreticulin down-regulates both GTP binding and transglutaminase activities of transglutaminase II.
Feng JF; Readon M; Yadav SP; Im MJ
Biochemistry; 1999 Aug; 38(33):10743-9. PubMed ID: 10451369
[TBL] [Abstract][Full Text] [Related]
38. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Woo SM; Min KJ; Chae IG; Chun KS; Kwon TK
Mol Carcinog; 2015 Mar; 54(3):216-28. PubMed ID: 24127286
[TBL] [Abstract][Full Text] [Related]
39. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
